Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Standard memory tests may not capture the full cognitive toll of breast cancer chemotherapy. A new study found that survivors performed worse on narrative memory tasks and reported greater mental effort, yet scored similarly to healthy controls on a widely used "gold standard" memory test. Researchers say clinicians should take patients' subjective cognitive complaints seriously.
Breast cancer survivors who underwent chemotherapy know the fog all too well — but a new study suggests the standard tests used to measure it may not be telling the whole story. Published in Translational Neuroscience, the research found that women post-chemotherapy performed significantly worse on narrative memory tasks and reported higher cognitive workloads compared to women with no cancer history. Yet on the Verbal Paired Associates (VPA) test — a widely used "gold standard" episodic memory measure — both groups scored similarly.
The disconnect points to a real gap: standard assessments may be missing the everyday memory deficits that breast cancer survivors actually experience. Researchers say this could lead to under-reporting of cognitive impairment and patients feeling dismissed when their concerns aren't validated by test results.
Key Takeaways:
Why it matters: If the tools used to assess cognitive impairment aren't sensitive enough to catch real-world deficits, patients may be left without proper support. Clinicians should listen to subjective reports, use ecologically valid assessments, and screen for compounding factors like hearing loss.
